Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase
A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp
A systematic analysis reveals that the pathogenicity of loss-of-function variants in MODY genes is gene-specific and dependent on nonsense-mediated decay status. Crucially, NMD-escape variants in the INS gene represent a novel, clinically d
Researchers have discovered that measuring oxygen partial pressure (pO2) can significantly improve the accuracy and speed of Adrenal Venous Sampling, providing a cost-effective tool for diagnosing Primary Aldosteronism.
A large-scale target trial emulation study demonstrates that SGLT2 inhibitors significantly reduce the initiation of allopurinol and the use of anti-inflammatory medications in patients with comorbid gout and type 2 diabetes, offering a pot
An international cohort study demonstrates that combining USP8 genotype with tumor size significantly improves the prediction of recurrence in Cushing’s disease, identifying high-risk patients even among those with low postoperative c
The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr
Obesity-induced insulin resistance hinders heart failure recovery post-LVAD by disrupting the pentose phosphate pathway. A new study in Circulation suggests insulin sensitizers could restore cardiac repair mechanisms in obese patients.
A systematic review and meta-analysis of 64 randomized trials reveals that GLP-1 receptor agonists lead to significantly higher weight loss in women (10.9%) compared to men (6.8%), while maintaining consistent efficacy across various ages,
A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.
The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injec
This randomized clinical trial demonstrates that proactive pharmacist outreach using evidence-based algorithms significantly improves prescribing safety and reduces emergency hypoglycemia events in high-risk patients with type 2 diabetes wi
The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite s
A large-scale randomized trial reveals that monthly produce subsidies do not significantly improve HbA1c or reduce healthcare utilization in food-insecure diabetes patients, suggesting that ‘Food is Medicine’ initiatives require
A massive study of 134,548 Mexicans reveals that Indigenous American genomic ancestry is a potent, independent risk factor for type 2 diabetes and prediabetes, highlighting an urgent need for population-specific preventive healthcare strate
A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em
A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.
This study reveals that combining stress hyperglycemia ratio and glucose variability significantly improves mortality prediction in sepsis, with risk patterns varying significantly based on a patient’s baseline metabolic status (Norma
Open language-specific specialty feeds and department pages.